Abstract
Gastrointestinal stromal tumors (GISTs) form an interesting group of sarcomas whose unique pathobiology provides a model of how molecularly targeted therapeutics can have a major impact on patient welfare. Approximately 85% of GISTs are driven by oncogenic mutations in either of two receptor tyrosine kinases: KIT or platelet-derived growth factor receptor α. We review the pivotal relationship between specific mutations in these kinase genes, the origin and pathologic spectrum of GISTs, and the response of these tumors to treatment with kinase inhibitors such as imatinib and sunitinib. Mechanisms of resistance to kinase inhibitor therapy are discussed, and targets for the next generation of therapeutics are considered. The rapid evolution in our understanding of GISTs, which stems directly from the close alliance of basic and clinical researchers in the field, illustrates the growing role of the molecular classification of solid tumors in the development of modern oncological treatments.
Keywords
SunitinibImatinibGiSTPDGFRACancer researchTyrosine kinaseStromal cellTyrosine-kinase inhibitorReceptor tyrosine kinaseTargeted therapyBiologyMedicineKinaseBioinformaticsCancerReceptorInternal medicineGenetics
Affiliated Institutions
Related Publications
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Purpose: Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) th...
Sunitinib: From Rational Design to Clinical Efficacy
Sunitinib (SU011248) is an oral small molecular tyrosine kinase inhibitor that exhibits potent antiangiogenic and antitumor activity. Tyrosine kinase inhibitors such as SU6668 a...
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT s...
Diagnosing and Managing Advanced Chronic Myeloid Leukemia
Clinical staging of chronic myeloid leukemia (CML) distinguishes between chronic phase (CP-CML), accelerated phase (AP-CML), and blastic phase (BP-CML), reflecting its natural h...
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib ...
Publication Info
- Year
- 2008
- Type
- review
- Volume
- 3
- Issue
- 1
- Pages
- 557-586
- Citations
- 310
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
310
OpenAlex
Cite This
Christopher L. Corless,
Michael C. Heinrich
(2008).
Molecular Pathobiology of Gastrointestinal Stromal Sarcomas.
Annual Review of Pathology Mechanisms of Disease
, 3
(1)
, 557-586.
https://doi.org/10.1146/annurev.pathmechdis.3.121806.151538
Identifiers
- DOI
- 10.1146/annurev.pathmechdis.3.121806.151538